Yan Q - Search Results

1

The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.

Jiang X, Liu Y, Chen C, Zhan Z, Yan Q, Guo Y, Wang Q, Li K. Jiang X, et al. Among authors: yan q. Clin Lung Cancer. 2012 Jul;13(4):288-96. doi: 10.1016/j.cllc.2011.11.004. Epub 2011 Dec 13. Clin Lung Cancer. 2012. PMID: 22169481

2

[Morphological and ultrastructural observation in the angiogenesis process of human lung adenocarcinoma cell LALU].

Yan Q, Zhan Z, Sun H, Sun B, Bai J, Yang H. Yan Q, et al. Zhongguo Fei Ai Za Zhi. 2001 Oct 20;4(5):330-2. doi: 10.3779/j.issn.1009-3419.2001.05.04. Zhongguo Fei Ai Za Zhi. 2001. PMID: 21059309 Free article. Chinese.

3

Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement.

Gao Q, Li P, Jiang X, Zhan Z, Yan Q, Zhang B, Huang C. Gao Q, et al. Among authors: yan q. Oncotarget. 2017 Sep 18;8(49):86066-86081. doi: 10.18632/oncotarget.20973. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156778 Free PMC article.

4

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma.

Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z, Huang C. Li P, et al. Among authors: yan q. J Cancer. 2019 Jan 1;10(1):61-71. doi: 10.7150/jca.26947. eCollection 2019. J Cancer. 2019. PMID: 30662526 Free PMC article.

5

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.

Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C. Li Z, et al. Among authors: yan q, yan b. Thorac Cancer. 2020 Jan;11(1):176-180. doi: 10.1111/1759-7714.13259. Epub 2019 Nov 25. Thorac Cancer. 2020. PMID: 31766077 Free PMC article.

6

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Zhang T, Wang J, Su Y, Chen X, Yan Q, Li Q, Sun L, Wang Y, Er P, Pang Q, Wang P. Zhang T, et al. Among authors: yan q. Oncotarget. 2017 Jun 20;8(25):40594-40605. doi: 10.18632/oncotarget.16505. Oncotarget. 2017. PMID: 28380449 Free PMC article.

7

Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.

Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y, Zhang Z, Su Y, Wang C. Zhang Q, et al. Among authors: yan q. Acta Biochim Biophys Sin (Shanghai). 2018 Aug 1;50(8):748-756. doi: 10.1093/abbs/gmy074. Acta Biochim Biophys Sin (Shanghai). 2018. PMID: 29961813 Free article.

8

Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.

Wang YN, Yao S, Wang CL, Li MS, Sun LN, Yan QN, Tang SW, Zhang ZF. Wang YN, et al. J Clin Oncol. 2018 Oct 10;36(29):2935-2942. doi: 10.1200/JCO.2018.78.7101. Epub 2018 Aug 27. J Clin Oncol. 2018. PMID: 30148659

9

A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung.

Liang R, Chen TX, Wang ZQ, Jin KW, Zhang LY, Yan QN, Zhang HH, Wang WP. Liang R, et al. Exp Ther Med. 2015 Jan;9(1):197-202. doi: 10.3892/etm.2014.2075. Epub 2014 Nov 17. Exp Ther Med. 2015. PMID: 25452802 Free PMC article.

10

MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway.

Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y, Zhang Z, Su Y, Wang C. Zhang Q, et al. Among authors: yan q. Cell Biochem Funct. 2018 Jun;36(4):194-202. doi: 10.1002/cbf.3331. Epub 2018 Apr 13. Cell Biochem Funct. 2018. PMID: 29653464 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,524 results

Search Page

Filters